Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence

References

• Hostiuc S, Buda O, Ion DA. Harmine for catatonic schizophrenia. A forgotten experiment. Schizophr Res. 2014;159(1):249–250.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39(7):789–794.
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Jr Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–583.
   PubMed Web of Science ®Google Scholar
• Millan MJ, Fone K, Steckler T, et al. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24(5):645–692.
   PubMed Web of Science ®Google Scholar
• Davis MC, Horan WP, Marder SR. Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol. 2014; 24(5):788–799.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017;74(7):675–684.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–899.
   PubMed Web of Science ®Google Scholar
• Galling B, Vernon JA, Pagsberg AK, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018;137(3):187–205.
   PubMed Web of Science ®Google Scholar
• Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(9):876–886.
   PubMed Web of Science ®Google Scholar
• Ulrich S, Ricken R, Adli M. Tranylcypromine in mind (part I): review of pharmacology. Eur Neuropsychopharmacol. 2017;27(8):697–713.
   PubMed Web of Science ®Google Scholar
• Ricken R, Ulrich S, Schlattmann P, et al. Tranylcypromine in mind (part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714–731.
   PubMed Web of Science ®Google Scholar
• Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967;113(497):349–365.
   PubMed Web of Science ®Google Scholar
• Salter M, Kenney A. Myocardial injury from tranylcypromine-induced hypertensive crisis secondary to excessive tyramine intake. Cardiovasc Toxicol. 2018;18(6):583–586.
   PubMed Web of Science ®Google Scholar
• Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J Clin Psychiatry. 2012;73(suppl 1):17–24.
   PubMedGoogle Scholar
• Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789–797.
   PubMed Web of Science ®Google Scholar
• Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm. 2018;125(11):1707–1717.
   PubMed Web of Science ®Google Scholar
• Schwartz TL. A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr. 2013;18(S1):22–33.
   Web of Science ®Google Scholar
• Melamed Y, Karniel E, Szor H. Phenelzine as a possible treatment for depression in schizophrenic patients. Isr J Psychiatry Relat Sci. 1996;33(3):211–212.
   PubMed Web of Science ®Google Scholar
• Roesch-Ely D, Speck L, Ulrich S, et al. Adjuvantes Tranylcypromin mit Antipsychotika der zweiten Generation in der Behandlung schizophrener Negativsymptomatik: Retrospektive Studie zur Therapieroutine von 53 Patienten und Kurzübersicht zur Literatur [Adjuvant tranylcypromine with second generation antipsychotic drugs in the treatment of schizophrenia with negative symptoms: Retrospective analysis of treatment routine of 53 patients and short review of the literature]. Psychopharmakother. 2011;18(2):66–74. German
   Google Scholar
• Schmidt LG, Grohmann R, Rüther E. Unerwünschte Wirkungen von Antidepressiva in der Routinebehandlung [Adverse effects of antidepressants in routine treatment]. Psychopharmakother. 1994;1(1):6–15. German
   Google Scholar
• Ulrich S, Ricken R, Buspavanich P, et al. Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression: a systematic review and comprehensive meta-analysis. J Clin Psychopharmacol. 2020;40(1):63–74.
   PubMed Web of Science ®Google Scholar
• Amiri A, Noorbala AA, Nejatisafa AA, et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol. 2008;23(2):79–86.
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Siris SG, Bermanzohn PC, et al. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 2005;162(2):388–390.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Weiner E, Kelly DL, et al. Rasagiline in the treatment of the persistent negative symptoms of schizophrenia. Schizophr Bull. 2015;41(4):900–908.
   PubMed Web of Science ®Google Scholar
• Atkinson RM, Ditman KS. Tranylcypromine: a review. Clin Pharmacol Ther. 1965;6(5):631–655.
   PubMed Web of Science ®Google Scholar
• EMA: Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia [Internet]. European Medicines Agency; c1995–2020. [cited 2019 Sep 19]. Available from: https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-including-depot-preparations-treatment-schizophrenia.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–9.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Weintraub M. Meta-analysis: a method for synthesizing research. Clin Pharmacol Ther. 1995;58(6):605–616.
   PubMed Web of Science ®Google Scholar
• Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5(52):52–56.
   PubMedGoogle Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100–28.
   PubMed Web of Science ®Google Scholar
• Vogt AH. The use of stelazine and parnate in chronic, withdrawn patients. Am J Psychiatry. 1961;118(3):256–257.
   PubMed Web of Science ®Google Scholar
• Hordern A, Somerville DM, Krupinski J. Does chronic schizophrenia respond to a combination of a neuroleptic and an antidepressant? J Nerv Ment Dis. 1962;134:361–376.
   PubMed Web of Science ®Google Scholar
• Schiele BC, Vestre ND, MacNaughton DV. Treatment of hospitalized schizophrenics with trifluoperazine plus tranylcypromine: a double-blind controlled study. Compr Psychiatry. 1963;4(2):66–79.
   PubMed Web of Science ®Google Scholar
• Bucci L. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology. 1987;91(1):104–108.
   PubMed Web of Science ®Google Scholar
• Buffaloe WJ, Sandifer MG. A study of combined therapy of stelazine and “parnate” (SKF 385) in chronic anergic schizophrenics. AJP. 1961;117(11):1030–1031.
   Web of Science ®Google Scholar
• Mena A, Heistad G, Schiele BC, et al. A comparison of tranylcypromine alone with tranylcypromine plus trifluoperazine in the treatment of chronic outpatients: a double-blind controlled study. J Neuropsychiatr. 1964;5:542–550.
   PubMed Web of Science ®Google Scholar
• Hedberg DL, Houck JH, Glueck BC. Tranylcypromine-trifluoperazine combination in the treatment of schizophrenia. Am J Psychiatry. 1971;127(9):1141–1146.
   PubMed Web of Science ®Google Scholar
• O'Connor K, Connor KO, Nelson B, et al. Pseudoneurotic schizophrenia revisited. Aust N Z J Psychiatry. 2009;43(9):873–876.
   PubMed Web of Science ®Google Scholar
• Janecek J, Schiele BC, Trousdale W, et al. Differential effects of psychotropic drugs. An exploration using comparisons of several agents. Dis Nerv Syst. 1965;26:292–301.
   PubMedGoogle Scholar
• Kruse W. Trifluoperazine and tranylcypromine in chronic refractory schizophrenics. Am J Psychiatry. 1960;117(6):548–549.
   PubMed Web of Science ®Google Scholar
• Singh H, Free RM. A preliminary report on the use of stelazine and parnate in chronic regressed and withdrawn patients. AJP. 1960;117(4):364–365.
   Web of Science ®Google Scholar
• Barsa JA, Saunders JC. Tranylcypromine in the treatment of chronic schizophrenics. Am J Psychiatry. 1962;118(4):933–934.
   PubMed Web of Science ®Google Scholar
• Barsa JA, Saunders JC. A comparative study of tranylcypromine and paragyline. Psychopharmacologia. 1964; 6(4):295–298.
   PubMed Web of Science ®Google Scholar
• Langner E. Die Behandlung psychotischer Antriebstörungen [The treatment of psychotic drive disorders]. Wien Med Wochenschr. 1968;118(36):700–702. German
   PubMedGoogle Scholar
• Siris SG, van Kammen DP, Docherty JP. Use of antidepressant drugs in schizophrenia. Arch Gen Psychiatry. 1978;35(11):1368–1377.
   PubMed Web of Science ®Google Scholar
• Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004(1):CD003545
   PubMedGoogle Scholar
• Nasrallah HA, Tandon R. Textbook of psychopharmacology. 5th ed. Arlington (VA): APA Publishing; 2017. Chapter 24, Classic antipsychotic medication; p. 603–621.
   Google Scholar
• Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192–208.
   PubMed Web of Science ®Google Scholar
• Emanuele E, Colombo R, Martinelli V, et al. Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuroendocrinol Lett. 2010;31(1):117–121.
   PubMed Web of Science ®Google Scholar
• Tanimukai H, Ginther R, Spaide J, et al. Occurrence of bufotenin (5-hydroxy-N,N-dimethyltryptamine) in urine of schizophrenic patients. Life Sci. 1967;6(16):1697–1706.
   PubMedGoogle Scholar
• Fischer E, Heller B. L’influence d’un inhibiteur de’l amino-oxidase sur l’elimination de la bufotenine et sur les symptomes de la schizophrenie chronique non productive [The influence of a monoamine oxidase inhibitor on the elimination of bufotenin and on the chronic non-productive schizophrenic symptoms]. Ann Med Psychol. 1965;123:614–622. French
   PubMedGoogle Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 3rd ed. Washington (DC): APA Publishing; 2021.
   Google Scholar
• Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3–78.
   PubMed Web of Science ®Google Scholar
• DGPPN e.V. (Editors) for the guideline group. S3-Leitlinie Schizophrenie. Langfassung. Version 1.0 [S3-Guideline for schizophrenia. Long version. Version 1.0]; 2019.
   Google Scholar
• Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525–1535.
   PubMed Web of Science ®Google Scholar
• Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005;80(1):85–97.
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences. New York: Routledge; 1988.
   Google Scholar
• Galderisi S, Merlotti E, Mucci A. Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2015;265(7):543–558.
   PubMed Web of Science ®Google Scholar
• Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5(47):1–11.
   PubMed Web of Science ®Google Scholar
• Da Silva Alves F, Figee M, van Amelsvoort T, et al. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull. 2008;41(1):121–132.
   PubMedGoogle Scholar
• Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 2007;78:1–39.
   PubMed Web of Science ®Google Scholar
• Maia TV, Frank MJ. An integrative perspective on the role of dopamine in schizophrenia. Biol Psychiatry. 2017;81(1):52–66.
   PubMed Web of Science ®Google Scholar
• Hampson DR, Baker GB, Coutts RT. Neurochemical changes in rat brain amines after short- and long-term inhibition of monoamine oxidase by a low dose of tranylcypromine. Biol Psychiatry. 1988;23(3):227–236.
   PubMed Web of Science ®Google Scholar
• Jones AB, Pare CM, Nicholson WJ, et al. Brain amine concentrations after monoamine oxidase inhibitor administration. Br Med J. 1972;1(5791):17–19.
   PubMed Web of Science ®Google Scholar
• Willner P. Dopamine and depression: a review of recent evidence. III. The effects of antidepressant treatments. Brain Res. 1983;287(3):237–246.
   PubMed Web of Science ®Google Scholar
• Ainsworth K, Smith SE, Zetterström TS, et al. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology. 1998;140(4):470–477.
   PubMed Web of Science ®Google Scholar
• Hyttel J. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171. Psychopharmacology. 1977;51(3):225–233.
   PubMed Web of Science ®Google Scholar
• Martin KF, Phillips I, Cheetham SC, et al. Dopamine D2 receptors: a potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments. Pharmacol Biochem Behav. 1995;51(4):565–569.
   PubMed Web of Science ®Google Scholar
• Sabe M, Kirschner M, Kaiser S. Prodopaminergic drugs for treating the negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Clin Psychopharmacol. 2019;39(6):658–664.
   PubMed Web of Science ®Google Scholar
• Marcolin MA, Davis JM. Platelet monoamine oxidase in schizophrenia: a meta-analysis. Schizophr Res. 1992;7(3):249–267.
   PubMed Web of Science ®Google Scholar
• Chue P, Lalonde JK. Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatr Dis Treat. 2014;10:777–789.
   PubMed Web of Science ®Google Scholar
• Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull. 2006;32(2):220–222.
   PubMed Web of Science ®Google Scholar
• Gillman PG, Feinberg SS, Fochtmann LJ. Revitalizing monoamine oxidase inhibitors: a call for action. CNS Spectr. 2020;25(4):452–454.
   PubMed Web of Science ®Google Scholar
• Hordern A, Somerville DM. Clinical trials in chronic schizophrenia. Med J Aust. 1963;50(1):40–43.
   PubMed Web of Science ®Google Scholar
• Janecek J, Schiele BC, Bellville T, et al. The effects of withdrawal of trifluoperazine on patients maintained on the combination of tranylcypromine and trifluoperazine: a double-blind study. Curr Ther Res Clin Exp. 1963;5:608–615.
   PubMed Web of Science ®Google Scholar
• Sharpley P, Mena A, Schiele BC, et al. A comparison of pargyline and tranylcypromine with and without the addition of trifluoperazine: a double-blind study. Curr Ther Res Clin Exp. 1964;6(5):344–352.
   PubMed Web of Science ®Google Scholar